‘No Deal’ Brexit? Australia Will Still Accept UK Notified Body Certificates
The Therapeutic Goods Administration has released a statement on the implications of Brexit for medical devices in Australia.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.